Literature DB >> 24251668

Diversion of prescribed opioids by people living with chronic pain: results from an Australian community sample.

Jessica Belcher1, Suzanne Nielsen, Gabrielle Campbell, Raimondo Bruno, Bianca Hoban, Briony Larance, Nicholas Lintzeris, Louisa Degenhardt.   

Abstract

INTRODUCTION AND AIMS: There has been an increase in prescription of opioids for chronic non-cancer pain, and concern exists over possible diversion of prescription opioids to the illicit marketplace. Recent media coverage suggests that elderly patients sell their prescribed opioids for additional income. This study investigated the extent to which an Australian community sample of chronic pain patients prescribed opioids reported supplying their prescribed opioids to others. DESIGN AND METHODS: Participants living with chronic non-cancer pain and prescribed opioids for their pain (n=952) were recruited across Australia via advertisements at pharmacies. A telephone interview included questions about their pain condition and opioid medication.
RESULTS: Participants had been living with pain for a mean of 14.2 years; most common conditions included chronic back/neck problems and arthritis/rheumatism. Around half (43%) were currently prescribed one opioid, and 55% had been prescribed 2-5 opioids; the most common was oxycodone. Forty-two participants (4%) reported ever supplying prescribed opioids to another person; one participant reported receiving payment. Participants who supplied opioids to others were younger (odds ratio 0.97, 95% confidence interval 0.95-0.99) and engaged in a greater number of aberrant behaviours relating to their opioid medication (odds ratio 1.77, 95% confidence interval 1.45-2.17), including tampering with doses, taking opioids by alternative routes, seeing doctors to obtain extra opioids and refilling prescriptions early. DISCUSSION AND
CONCLUSION: Few people with chronic non-cancer pain divert their opioids to others. Media reports of elderly patients selling their opioids to supplement their income may be reflective of exceptional cases. Future studies may investigate the extent to which other patient groups divert prescription opioids to the illicit marketplace.
© 2013 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Keywords:  chronic pain; diversion; non-adherence; pharmaceutical opioids

Mesh:

Substances:

Year:  2013        PMID: 24251668     DOI: 10.1111/dar.12084

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  6 in total

1.  Potential for Harm Associated with Discharge Opioids After Hospital Stay: A Systematic Review.

Authors:  Gerardo A Arwi; Stephan A Schug
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

2.  The risks of opioid treatment: Perspectives of primary care practitioners and patients from safety-net clinics.

Authors:  Emily E Hurstak; Margot Kushel; Jamie Chang; Rachel Ceasar; Kara Zamora; Christine Miaskowski; Kelly Knight
Journal:  Subst Abus       Date:  2017-04-10       Impact factor: 3.716

3.  Prescription opioid use disorder and heroin use among 12-34 year-olds in the United States from 2002 to 2014.

Authors:  Silvia S Martins; Luis E Segura; Julian Santaella-Tenorio; Alexander Perlmutter; Miriam C Fenton; Magdalena Cerdá; Katherine M Keyes; Lilian A Ghandour; Carla L Storr; Deborah S Hasin
Journal:  Addict Behav       Date:  2016-08-30       Impact factor: 3.913

Review 4.  GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.

Authors:  Francesco P Busardò; Alan W Jones
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

5.  OPAL: a randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal pain. Trial protocol.

Authors:  Chung-Wei Christine Lin; Andrew J McLachlan; Jane Latimer; Ric O Day; Laurent Billot; Bart W Koes; Chris G Maher
Journal:  BMJ Open       Date:  2016-08-24       Impact factor: 2.692

6.  Counseling interactions between patients living with persistent pain and pharmacists in Australia: are we on the same page?

Authors:  Esther Tl Lau; Shirin H Tan; Yasmin J Antwertinger; Tony Hall; Lisa M Nissen
Journal:  J Pain Res       Date:  2019-08-05       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.